Position in HLN
as of Mar 31, 2026
· filed May 13, 2026
Position Value
$180
New position
Shares Held
18
first reported quarter
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 0.ToString("F0")%
Shared 0.ToString("F0")%
None 100.ToString("F0")%
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Mar 31, 2026Triumph Capital Management holds $61,097 across 9 Drug Manufacturers - Specialty & Generic names. HLN ranks #6 (0.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | TAK |
Takeda Pharmaceutical Co Ltd
|
1,079 | $19,983 | |
| 2 | TEVA |
Teva Pharmaceutical Industries Ltd
|
550 | $16,566 | |
| 3 | VTRS |
Viatris Inc
|
1,039 | $14,036 | |
| 4 | EBS |
Emergent BioSolutions Inc.
|
700 | $5,810 | |
| 5 | ZTS |
Zoetis Inc.
|
37 | $4,373 | |
| 6 | HLN |
Haleon plc
This page
|
18 | $180 | |
| 7 | SIGA |
Siga Technologies Inc
|
25 | $133 | |
| 8 | CRON |
Cronos Group Inc.
|
6 | $15 |
All Filings in HLN
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $180 | 18 | Shares | Sole | 2026-05-13 | |
| No filing history on record for this holder in this stock. | ||||||